P N Patsalos

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi request reprint The importance of drug interactions in epilepsy therapy
    Philip N Patsalos
    Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, England, UK
    Epilepsia 43:365-85. 2002
  2. ncbi request reprint Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs
    Philip N Patsalos
    Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, London, UK
    Lancet Neurol 2:473-81. 2003
  3. ncbi request reprint Clinical pharmacokinetics of levetiracetam
    Philip N Patsalos
    Pharmacology and Therapeutics Unit, Department of Clinical and Experimental Epilepsy, Institute of Neurology The National Hospital for Neurology and Neurosurgery, London, UK
    Clin Pharmacokinet 43:707-24. 2004
  4. ncbi request reprint The pharmacokinetic characteristics of levetiracetam
    P N Patsalos
    Institute of Neurology The National Hospital for Neurology and Neurosurgery, Pharmacology and Therapeutics Unit, Department of Clinical and Experimental Epilepsy, London, UK
    Methods Find Exp Clin Pharmacol 25:123-9. 2003
  5. ncbi request reprint Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies
    Philip N Patsalos
    Pharmacology and Therapeutics Unit, Department of Clinical and Experimental Epilepsy, Institute of Neurology, London, United Kingdom
    Epilepsia 46:140-8. 2005
  6. ncbi request reprint Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs
    Philip N Patsalos
    Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, London, UK
    Lancet Neurol 2:347-56. 2003
  7. ncbi request reprint In situ metabolism of levetiracetam in blood of patients with epilepsy
    Philip N Patsalos
    Pharmacology and Therapeutics Unit, Department of Clinical and Experimental Epilepsy, Institute of Neurology, London, United Kingdom
    Epilepsia 47:1818-21. 2006
  8. ncbi request reprint Pharmacokinetic profile of levetiracetam: toward ideal characteristics
    P N Patsalos
    Institute of Neurology, Pharmacology and Therapeutics Unit, University Department of Clinical Neurology, London, UK
    Pharmacol Ther 85:77-85. 2000
  9. doi request reprint Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies
    Philip N Patsalos
    Institute of Neurology The National Hospital for Neurology and Neurosurgery, London and The Chalfont Centre for Epilepsy, Chalfont St Peter, United Kingdom
    Epilepsia 49:1239-76. 2008
  10. ncbi request reprint Caffeine has no effect on measures of cortical excitability
    M Orth
    Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Royal Free and University College Medical School, London, UK
    Clin Neurophysiol 116:308-14. 2005

Detail Information

Publications45

  1. ncbi request reprint The importance of drug interactions in epilepsy therapy
    Philip N Patsalos
    Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, England, UK
    Epilepsia 43:365-85. 2002
    ....
  2. ncbi request reprint Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs
    Philip N Patsalos
    Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, London, UK
    Lancet Neurol 2:473-81. 2003
    ..Careful monitoring of clinical response is recommended whenever a drug is added or removed from a patient's AED regimen...
  3. ncbi request reprint Clinical pharmacokinetics of levetiracetam
    Philip N Patsalos
    Pharmacology and Therapeutics Unit, Department of Clinical and Experimental Epilepsy, Institute of Neurology The National Hospital for Neurology and Neurosurgery, London, UK
    Clin Pharmacokinet 43:707-24. 2004
    ..Overall, the pharmacokinetic characteristics of levetiracetam are highly favourable and make its clinical use simple and straightforward...
  4. ncbi request reprint The pharmacokinetic characteristics of levetiracetam
    P N Patsalos
    Institute of Neurology The National Hospital for Neurology and Neurosurgery, Pharmacology and Therapeutics Unit, Department of Clinical and Experimental Epilepsy, London, UK
    Methods Find Exp Clin Pharmacol 25:123-9. 2003
    ..Overall, the pharmacokinetic characteristics of levetiracetam can be considered highly desirable...
  5. ncbi request reprint Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies
    Philip N Patsalos
    Pharmacology and Therapeutics Unit, Department of Clinical and Experimental Epilepsy, Institute of Neurology, London, United Kingdom
    Epilepsia 46:140-8. 2005
    ..Levetiracetam rates highest with topiramate in second place...
  6. ncbi request reprint Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs
    Philip N Patsalos
    Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, London, UK
    Lancet Neurol 2:347-56. 2003
    ..Interactions involving enzyme inhibition include the increase in plasma concentrations of lamotrigine and phenobarbital caused by valproic acid. Among AEDs, the least potential interaction is associated with gabapentin and levetiracetam...
  7. ncbi request reprint In situ metabolism of levetiracetam in blood of patients with epilepsy
    Philip N Patsalos
    Pharmacology and Therapeutics Unit, Department of Clinical and Experimental Epilepsy, Institute of Neurology, London, United Kingdom
    Epilepsia 47:1818-21. 2006
    ....
  8. ncbi request reprint Pharmacokinetic profile of levetiracetam: toward ideal characteristics
    P N Patsalos
    Institute of Neurology, Pharmacology and Therapeutics Unit, University Department of Clinical Neurology, London, UK
    Pharmacol Ther 85:77-85. 2000
    ..This profile may facilitate the clinical management of patients with epilepsy by providing a safer and less-complicated therapeutic strategy...
  9. doi request reprint Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies
    Philip N Patsalos
    Institute of Neurology The National Hospital for Neurology and Neurosurgery, London and The Chalfont Centre for Epilepsy, Chalfont St Peter, United Kingdom
    Epilepsia 49:1239-76. 2008
    ..g., in pregnancy, or when an interacting drug is added or removed); (6) to guide dose adjustments for AEDs with dose-dependent pharmacokinetics, particularly phenytoin...
  10. ncbi request reprint Caffeine has no effect on measures of cortical excitability
    M Orth
    Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Royal Free and University College Medical School, London, UK
    Clin Neurophysiol 116:308-14. 2005
    ..To assess the effect of caffeine on motor thresholds, short interval intra-cortical inhibition (SICI), intra-cortical facilitation (ICF) and cortical silent periods in a placebo controlled double-blinded trial...
  11. ncbi request reprint Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction
    Sanjay M Sisodiya
    Pharmacology and Therapeutics Unit, Department of Clinical and Experimental Epilepsy, University College London, UK
    Epilepsy Res 48:217-9. 2002
    ..Therefore, during levetiracetam co-medication with carbamazepine, patients should be monitored closely for symptoms of carbamazepine toxicity...
  12. ncbi request reprint Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy
    Yvonne M Langan
    Department of Clinical and Experimental Epilepsy, Institute of Neurology, London, and The National Society for Epilepsy, Chalfont St Peter, UK
    Epilepsia 44:46-53. 2003
    ..This study examines the single- and multiple-dose pharmacokinetics, safety, and tolerability of talampanel in patients with intractable epilepsy and assesses the potential for pharmacokinetic interaction...
  13. pmc A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain
    X Tong
    Pharmacology and Therapeutics Unit, University Department of Clinical Neurology, Institute of Neurology, Queen Square, London
    Br J Pharmacol 133:867-74. 2001
    ..Its prolonged efflux from and slow equilibration within the brain may explain, in part, its long duration of action. The concurrent changes in taurine may contribute to its mechanism of action...
  14. pmc Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine
    M C Walker
    Epilepsy Research Group, Pharmacology and Therapeutics Unit, University Department of Clinical Neurology, Institute of Neurology, Queen Square, London WC1N 3BG
    Br J Pharmacol 130:242-8. 2000
    ..Furthermore, the free serum drug concentration is not the sole contributor to the CSF compartment, and the CSF concentration is an overestimate of the bECF concentration of lamotrigine...
  15. pmc Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide
    J Semba
    Epilepsy Research Group, University Department of Clinical Neurology, Queen Square, London
    Br J Pharmacol 108:1117-24. 1993
    ..6. In conclusion, serum milacemide rapidly enters and equilibrates with the CNS compartment where it is metabolised primarily by MAO-B to glycinamide and finally to glycine. Metabolism in the peripheral compartment is negligible...
  16. ncbi request reprint Comparison of single- and repeated-dose pharmacokinetics of diazepam
    M C Walker
    University Department of Clinical Neurology, Institute of Neurology, London, UK
    Epilepsia 39:283-9. 1998
    ....
  17. ncbi request reprint A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy
    Clare Greenaway
    Department of Clinical and Experimental Epilepsy, Pharmacology and Therapeutics Unit, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Ther Drug Monit 32:448-52. 2010
    ....
  18. ncbi request reprint Cortical excitability predicts seizures in acutely drug-reduced temporal lobe epilepsy patients
    M A S Y Wright
    Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, UK
    Neurology 67:1646-51. 2006
    ..To test the hypothesis that cortical excitability changes prior to seizures, using transcranial magnetic brain stimulation (TMS)...
  19. ncbi request reprint Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat
    S Nagaki
    Pharmacolgy and Therapeutics Unit, University Department of Clinical Neurology, Institute of Neurology, London, UK
    Eur J Drug Metab Pharmacokinet 24:255-64. 1999
    ..CSF mean t(1/2) values for primidone, phenylethylmalonamide and phenobarbital were similar to those of sera and essentially paralleled the pattern seen in sera...
  20. pmc A comparison of the efficacy of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy
    H C Doheny
    Pharmacology and Therapeutics Unit, Department of Clinical and Experimental Epilepsy, Institute of Neurology, Queen Square, London WC1N 3BG, UK
    Br J Pharmacol 135:1425-34. 2002
    ..Furthermore, levetiracetam probably does not act by preventing ictogenesis per se but acts to reduce seizure severity and seizure generalization...
  21. ncbi request reprint The pharmacokinetics of vigabatrin in rat blood and cerebrospinal fluid
    X Tong
    Department of Clinical and Experimental Epilepsy, Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom
    Seizure 16:43-9. 2007
    ..We therefore investigated the rate of penetration into and the inter-relationship between serum and CSF compartments following systemic administration of vigabatrin in the rat...
  22. ncbi request reprint Omega-3 fatty acid supplementation in patients with chronic epilepsy: a randomized trial
    Alan W C Yuen
    Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
    Epilepsy Behav 7:253-8. 2005
    ..No change in serum AED concentrations was detected. Further studies are required to examine different omega-3 FA preparations, different doses, longer treatment duration, and larger sample sizes...
  23. ncbi request reprint The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus)
    Xiaolan Wang
    Pharmacology and Therapeutics Unit, Department of Clinical and Experimental Epilepsy, Institute of Neurology, Queen Square, London WC1N 3BG, UK
    Seizure 13:574-81. 2004
    ..We therefore sought to investigate serum, cerebrospinal fluid (CSF) and frontal cortex and hippocampal extracellular fluid (ECF) kinetic inter-relationship of tiagabine in a freely moving rat model...
  24. ncbi request reprint Erythrocyte and plasma fatty acid profiles in patients with epilepsy: does carbamazepine affect omega-3 fatty acid concentrations?
    Alan W C Yuen
    Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
    Epilepsy Behav 12:317-23. 2008
    ....
  25. ncbi request reprint Synergism between topiramate and budipine in refractory status epilepticus in the rat
    Andrew Fisher
    Department of Clinical and Experimental Epilepsy, Institute of Neurology, UCL, London, United Kingdom
    Epilepsia 45:1300-7. 2004
    ..To evaluate the antiepileptic and neuroprotective properties of topiramate (TPM) alone and with coadministration of the N-methyl-D-aspartate (NMDA)-receptor antagonist budipine in a rat model of refractory status epilepticus...
  26. doi request reprint Vigabatrin extracellular pharmacokinetics and concurrent gamma-aminobutyric acid neurotransmitter effects in rat frontal cortex and hippocampus using microdialysis
    Xin Tong
    Department of Clinical and Experimental Epilepsy, Pharmacology and Therapeutics Unit, Institute of Neurology, London, United Kingdom
    Epilepsia 50:174-83. 2009
    ..hippocampus) and to ascertain the relationship between brain extracellular vigabatrin concentrations and concurrent gamma-aminobutyric acid (GABA) concentrations...
  27. pmc Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study
    R Katzenschlager
    National Hospital for Neurology and Neurosurgery, London, UK
    J Neurol Neurosurg Psychiatry 75:1672-7. 2004
    ..We have assessed the clinical effects and levodopa (L-dopa) pharmacokinetics following two different doses of mucuna preparation and compared them with standard L-dopa/carbidopa (LD/CD)...
  28. pmc The use of microdialysis for the study of drug kinetics: some methodological considerations illustrated with antipyrine in rat frontal cortex
    P N Patsalos
    Pharmacology and Therapeutics Unit, University Department of Clinical Neurology, Queen Square, London
    Br J Pharmacol 115:503-9. 1995
    ..These considerations are particularly important in relation to microdialysis studies of pharmacokinetic-pharmacodynamic interrelationships and modelling...
  29. ncbi request reprint A comparison of central brain (cerebrospinal and extracellular fluids) and peripheral blood kinetics of phenytoin after intravenous phenytoin and fosphenytoin
    Xiaolan Wang
    Pharmacology and Therapeutics Unit, Department of Clinical and Experimental Epilepsy, Institute of Neurology, Queen Square, London, UK
    Seizure 12:330-6. 2003
    ..Thus, overall, the central and peripheral kinetics of PHT are indistinguishable after PHT and FosPHT...
  30. ncbi request reprint Long-term cohort study comparing medical (oxcarbazepine) and surgical management of intractable trigeminal neuralgia
    Joanna M Zakrzewska
    Oral Medicine, Dental Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Turner Street, 1E 2AD, London, UK
    Pain 95:259-66. 2002
    ..As these data cannot be extrapolated to other antineuralgic drugs, similar comparative studies would be appropriate...
  31. ncbi request reprint Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model
    Jarogniew J Luszczki
    Department of Pathophysiology, Medical University of Lublin, Jaczewskiego, Lublin, Poland
    Epilepsia 48:806-15. 2007
    ..The present study sought to ascertain the potential usefulness of levetiracetam (LEV) and felbamate (FBM) in combination in the mouse maximal electroshock (MES)-induced seizure model...
  32. ncbi request reprint Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis
    Jarogniew J Luszczki
    Department of Pathophysiology, Medical University of Lublin, Lublin, Poland
    Epilepsia 47:1841-54. 2006
    ....
  33. ncbi request reprint Isobolographic analysis of interactions between remacemide and conventional antiepileptic drugs in the mouse model of maximal electroshock
    Kinga K Borowicz
    Department of Pathophysiology, Medical University, Lublin, Poland
    Epilepsy Behav 11:6-12. 2007
    ..However, the concurrent pharmacokinetic interactions associated with remacemide complicate these observations and do not make remacemide a good candidate for adjunctive treatment of epilepsy...
  34. ncbi request reprint Interactions between zonisamide and conventional antiepileptic drugs in the mouse maximal electroshock test model
    Kinga K Borowicz
    Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, PL 20 090 Lublin, Poland
    Eur Neuropsychopharmacol 17:265-72. 2007
    ..Finally, one can conclude that because of the synergistic pharmacodynamic interaction between ZNS and VPA, this combination might be useful in clinical practice...
  35. ncbi request reprint Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model
    Jarogniew J Luszczki
    Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, 20 090, Lublin, Poland
    Naunyn Schmiedebergs Arch Pharmacol 373:169-81. 2006
    ..Furthermore, the fact that LCZ and PB have similar mechanisms of action would suggest that drugs with similar mechanisms of action may provide rational polytherapy regimens...
  36. ncbi request reprint Therapeutic drug monitoring of the newer antiepileptic drugs
    Svein I Johannessen
    The National Center for Epilepsy, Sandvika, Norway, Carlo Besta, Milan, Italy
    Ther Drug Monit 25:347-63. 2003
    ..Although routine monitoring in general cannot be recommended at present, measurements of some of the drugs is undoubtedly of help with individualization of treatment in selected cases in a particular clinical setting...
  37. ncbi request reprint Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data
    John Williams
    Subcommission on Therapeutic Drug Monitoring and Pharmacokinetics, ILAE Commission on Therapeutic Strategies, Department of Pharmacology, Therapeutics and Toxicology, University of Wales College of Medicine, Heath Park, Cardiff, Wales
    Epilepsia 44:40-5. 2003
    ..To assess interlaboratory variability in the determination of serum levels of new antiepileptic drugs (AEDs)...
  38. ncbi request reprint Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model
    Jarogniew J Luszczki
    Department of Pathophysiology, Skubiszewski Medical University of Lublin, Lublin, Poland
    Epilepsia 46:344-55. 2005
    ....
  39. ncbi request reprint Pharmacodynamic and/or pharmacokinetic characteristics of interactions between loreclezole and four conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis
    Jarogniew J Luszczki
    Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, PL 20 090 Lublin, Poland
    Epilepsy Behav 7:639-51. 2005
    ..75-0.91) used in this study. However, these conclusions are confounded by the fact that LCZ is associated with significant pharmacokinetic interactions...
  40. ncbi request reprint Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis
    Jarogniew J Luszczki
    Department of Pathophysiology, Medical University of Lublin, Lublin, Poland
    Epilepsia 47:10-20. 2006
    ..Brain AED concentrations were determined to ascertain any pharmacokinetic contribution to the observed antiseizure effect...
  41. ncbi request reprint Isobolographic analysis of interactions between losigamone and conventional antiepileptic drugs in the mouse maximal electroshock model
    Kinga K Borowicz
    Department of Pathophysiology, Lublin Medical University, Jaczewskiego 8, 20 090 Lublin, Poland
    Eur Neuropsychopharmacol 17:94-101. 2007
    ....
  42. ncbi request reprint Levetiracetam selectively potentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in mice
    Jarogniew J Luszczki
    Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, 20 090 Lublin, Poland
    Eur Neuropsychopharmacol 15:609-16. 2005
    ..These data support both experimental and clinical published data advocating that LEV may interact with some AEDs by pharmacodynamic mechanisms...
  43. ncbi request reprint Treatment of phenytoin toxicity by the molecular adsorbents recirculating system (MARS)
    Sambit Sen
    Institute of Hepatology, University College London Medical School and University College London Hospitals, England
    Epilepsia 44:265-7. 2003
    ..We attempted to demonstrate that severe PHT toxicity can be treated successfully with the Molecular Adsorbents Recirculating System (MARS). The mechanism of drug removal by the system also was studied...
  44. doi request reprint Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy
    Jarogniew J Luszczki
    Department of Pathophysiology, Medical University, Lublin, Poland
    Eur J Pharmacol 595:13-21. 2008
    ..Vigabatrin and gabapentin have a favorable pharmacodynamic interaction in animal seizure models in the absence of acute adverse effects or concurrent pharmacokinetic changes...
  45. ncbi request reprint Vigabatrin, but not gabapentin or topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina
    Graeme J Sills
    Epilepsy Unit, University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland
    Epilepsia 44:886-92. 2003
    ..We compared the concentration-related effects of VGB in rat brain and eye with those of gabapentin (GBP) and topiramate (TPM), both of which have been reported to elevate brain GABA concentrations in humans...